WuXi XDC's Singapore BCM3 Dual-Function Line Achieves GMP Release — First Overseas Capacity Milestone

BCM3 offers 200–2,000 L antibody-intermediate batches and up to 2,000 L conjugated drug substance batches. From announcement to GMP release took only two and a half years, marking a new stage in the company's "China + Singapore" dual-site global capacity layout.

On August 17, 2026, WuXi XDC (2268.HK), the global leading bioconjugate CRDMO, announced that BCM3 — the dual-function line for antibody intermediates and conjugated drug substance at its Singapore site — has successfully completed GMP release. This is the company's first overseas facility to pass GMP release, marking a new stage of its global capacity expansion.

Designed around an efficient, flexible "dual-function" concept, BCM3 provides one-stop commercial manufacturing from antibody intermediates to conjugated drug substance: antibody-intermediate batches range from 200 L to 2,000 L, while conjugated drug substance batches reach up to 2,000 L — fully meeting commercial-scale demand under a strict quality control system. BCM3 will work in synergy with the BCM1 and BCM2 lines in Wuxi, materially lifting overall capacity.

During construction, WuXi XDC combined its Wuxi plant-building experience with local Singapore conditions, overcoming multiple design and construction challenges in highly potent and highly toxic production areas. From the announcement in March 2024, to mechanical completion in June 2025, to GMP release — the entire journey took just two and a half years, another demonstration of "WuXi speed".

CEO Dr. Li Jincai commented: "The successful GMP release of BCM3, our first overseas manufacturing facility, is an important milestone in WuXi XDC's global footprint. Leveraging the 'China + Singapore' dual-site advantage, we will significantly enhance flexible delivery for diversified orders and provide solid capacity assurance for clients' commercial production."